FDA Approves Brain Tumor Drug Targeting New Mutation

(MedPage Today) — The FDA granted accelerated approval to dordaviprone (Modeyso) as the first systemic therapy for adults and children with diffuse midline glioma harboring H3 K27M mutations.
Labeling stipulates use in individuals 1 year and…